

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application. The claims have also been amended to delete multiple dependencies and to place the application into better form for examination. Entry of the present amendment and favorable action on the above-identified application are earnestly solicited.


Attached hereto is a marked-up copy of the changes made to the application by this Amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By


John W. Bailey, #32,881

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

JWB/cqc
0020-4828P

Attachment: Version with Markings to Show Changes Made

(Rev. 01/22/01)

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The specification was amended to provide cross-referencing to the International Application.

The claims have been amended as follows:

5. (Amended) The sustained release preparation of a lipophilic drug as claimed in [any one of Claims 1-4]Claim 1 or 2 wherein the water-soluble substance is an amphipathic substance.

6. (Amended) The sustained release preparation of a lipophilic drug as claimed in [any one of Claims 1-4]Claim 1 or 2 wherein the water-soluble substance is polyethylene glycol, polyoxyethylene polyoxypropylene glycol, or sucrose esters of fatty acids.

7. (Amended) The sustained release preparation of a lipophilic drug as claimed in [any one of Claims 1-4]Claim 1 or 2 wherein the water-soluble substance is sodium lauryl sulfate or sodium desoxycholic acid.

8. (Amended) The sustained release preparation of a lipophilic drug as claimed in [any one of Claims 1-4]Claim 1 or 2 wherein the water-soluble substance is sugars.

9. (Amended) The sustained release preparation of a lipophilic drug as claimed in [any one of Claims 1-4]Claim 1 or 2 wherein the water-soluble substance is an amino acid.

10. (Amended) The sustained release preparation of a lipophilic drug as claimed in [any one of Claims 1-4]Claim 1 or 2 wherein the water-soluble substance is a water-soluble drug.

11. (Amended) The sustained release preparation of a lipophilic drug as claimed in [any one of Claims 1-10]Claim 1 or 2 wherein the lipophilic drug is ivermectin, ceftiofur, dexamethasone, or estradiol.